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Interleukin-17 as a Molecular Target in
Immune-Mediated Arthritis
Immunoregulatory Properties of Genetically Modified Murine Dendritic Cells
That Secrete Interleukin-4
Sujata Sarkar, Laura A. Tesmer, Vindhya Hindnavis, Judith L. Endres, and David A. Fox
Objective. Our previous studies have shown that
murine dendritic cells (DCs) genetically modified to
express interleukin-4 (IL-4) reduce the incidence and
severity of murine collagen-induced arthritis. The
present studies were performed to assess the immuno-
regulatory mechanisms underlying this response, by
assessing the effects of IL-4 DCs on cytokine production
by subsets of T helper cells.
Methods. Male DBA mice ages 6–8 weeks old were
immunized with type II collagen. Splenic T cells ob-
tained during the initiation phase and the end stage of
arthritis were cultured with IL-4 DCs or untransduced
DCs in the presence of collagen rechallenge.
Interferon- (IFN) and IL-17 responses were mea-
sured. Antibodies to IL-4, IL-12, and IL-23, and recom-
binant IL-4, IL-12, and IL-23 were used to further study
the regulation of T cell cytokine production by IL-4 DCs.
Results. Splenic T cells obtained during the initi-
ation phase of arthritis produced less IL-17 when cul-
tured in the presence of IL-4 DCs, despite their produc-
tion of increased quantities of other proinflammatory
cytokines (IFN and tumor necrosis factor). T cell IL-17
production after collagen rechallenge was not inhibited
by a lack of IL-23, since IL-4–mediated suppression of
IL-17 was not reconstituted by IL-23, an otherwise
potent inducer of IL-17 production by T cells. Although
IL-4 DCs can produce increased quantities of IL-12 and
IFN, suppression of IL-17 production by IL-4 DCs was
independent of both. While IL-17 production by T cells
obtained during the initiation phase of arthritis was
regulated by IL-4 DCs, IL-17 production by T cells
obtained during end-stage arthritis was not altered.
Conclusion. Our data suggest that IL-4 DCs exert
a therapeutic effect on collagen-induced arthritis by
targeting IL-17. IL-17 suppression by IL-4 DCs is
robust and is not reversed by IL-23. Timing might be
important in IL-17–targeted therapy, since IL-17 pro-
duction by T cells obtained during end-stage arthritis
did not respond to suppression by IL-4 DCs.
Numerous cytokines are associated with the
pathogenesis of rheumatoid arthritis (RA), including
tumor necrosis factor (TNF), interferon- (IFN),
interleukin-1 (IL-1), IL-6, IL-15, and IL-17. IL-17 is a
proinflammatory cytokine that is secreted by T lympho-
cytes (1). Ligation of the IL-17 receptor, which is
expressed on several cell types, including epithelial cells,
endothelial cells, and fibroblasts, induces the secretion
of IL-6, IL-8, granulocyte colony-stimulating factor (G-
CSF), monocyte chemotactic protein 1, prostaglandin E2
(PGE2), TNF, and IL-1 (2–5), as well as neutrophil
chemotaxis and granulopoiesis (6,7). IL-17 induces the
expression of matrix metalloproteinase 1 (MMP-1) and
MMP-13 in RA synovial cells and osteoblasts (8,9).
IL-17 is present in RA synovium (10) and induces the
expression of RANKL, which contributes to bone re-
sorption (11,12). Local overexpression of IL-17 in-
creases the severity of murine arthritis, and neutralizing
anti–IL-17 antibody reduces the severity of arthritis
(13,14). IL-17–deficient mice have a reduced incidence
and severity of collagen-induced arthritis (CIA) (15).
Supported by the Arthritis Foundation and by NIH grant
AR-048310.
Sujata Sarkar, MD, Laura A. Tesmer, BS, Vindhya Hindnavis,
MD, Judith L. Endres, BS, David A. Fox, MD: University of Michigan,
Ann Arbor.
Address correspondence and reprint requests to David A.
Fox, MD, Division of Rheumatology, Room 3918 Taubman Center,
University of Michigan, 1500 East Medical Center Drive, Ann Arbor,
MI 48109. E-mail: dfox@umich.edu.
Submitted for publication April 25, 2006; accepted in revised
form September 29, 2006.
89
Taken together, the available data suggest that IL-17 is
important in both CIA and RA.
IL-23, a dimeric cytokine composed of the IL-12
p40 subunit and a unique p19 subunit (16), is secreted by
dendritic cells (DCs) and induces the production of
IL-17 by T cells (17,18). IL-23 p19–/– mice are resistant
to experimental autoimmune encephalomyelitis and
CIA, suggesting that this cytokine is important in auto-
immune diseases (19,20). There is some evidence that
costimulatory molecules may also be involved in the
regulation of IL-17, since IL-17 production is reduced in
ICOS–/– mice (21,22).
DCs are professional antigen-presenting cells
that are capable of activating and regulating T lympho-
cytes (23). Previous studies in our laboratory have shown
that a single injection of bone marrow–derived DCs
genetically engineered to express IL-4 reduces the inci-
dence and severity of CIA and alters primary immune
responses in vivo (24,25). Such effects were not pro-
duced by T cells or by fibroblasts overexpressing IL-4,
which suggests that the migratory properties of DCs are
required. Although genetically modified DCs were only
detectable in the spleen for a few days following injec-
tion, the effects of IL-4 DCs were long-lasting. Soluble
IL-4 has a short half-life and has to be administered by
continuous infusion or by repeated injections, whereas
IL-4 DCs can be administered as a single injection and
are effective in CIA, making this an attractive therapeu-
tic approach. The molecular mechanisms by which IL-4
DCs alter an ongoing immune response in vivo are not
yet understood in detail, although previous studies have
shown that the polyclonal response of splenic T cells
shifts to Th2 after administration of IL-4 DCs. However,
there is no evidence for the suppression of IL-12 expres-
sion in IL-4 DCs despite a down-regulation of the
expression of the IL-23 p19 subunit (25).
RA has been viewed as a Th1 disease, mediated
in part by the expression and biologic effects of IFN.
IFN, but not IL-4, is detected in the RA synovium (26).
However, deficiency of either IFN or the IFN recep-
tor causes an acceleration of CIA in mice (27). Further-
more, treatment of CIA with IL-4 DCs did not appear to
deplete primed collagen II–specific Th1 cells in vivo
(24). The existence of a third Th population, a distinct
subset of IL-17–producing T cells (Th17), was recently
proposed, which may be the pathogenic population in
some autoimmune diseases (15,17,28,29). The present
studies were performed to further our understanding of
the mechanisms underlying the response to IL-4 DCs in
CIA. We evaluated T lymphocyte responses to IL-4 DCs
during different phases of arthritis, and we found that
IL-4 DCs selectively regulate the production of IL-17.
MATERIALS AND METHODS
Purification and stimulation of dendritic cells. Bone
marrow–derived DCs and IL-4 DCs were derived from DBA
mice as previously described (24). DCs were purified on day 5
of culture using CD11c Microbeads (Miltenyi Biotech). Den-
dritic cell purity was 90–99%. For some experiments, DCs and
IL-4 DCs were then stimulated with 10 g/ml of soluble
CD40L (Research Diagnostics, Flanders, NJ) for 24 hours,
with or without 40 ng/ml of recombinant IL-4 (R&D Systems,
Minneapolis, MN) added to the DCs or 10 g/ml of neutral-
izing antibody to IL-4 (clone 11B11; BD PharMingen) added
to the IL-4 DCs. Culture supernatants were collected and
frozen for later cytokine analysis.
Cytokine enzyme-linked immunosorbent assay
(ELISA). Cytokine production in culture supernatants was
analyzed by ELISA. Kits for measuring IL-6, TNF, IL-10,
IFN, IL-4, and IL-17 were obtained from BD PharMingen
(San Diego, CA).
Purification of T lymphocytes. Male DBA mice (The
Jackson Laboratory, Bar Harbor, ME) ages 6–10 weeks were
immunized at the base of the tail with an intradermal injection
of chicken type II collagen and Freund’s complete adjuvant
(CFA; Chondrex, Redmond, WA). Mice were killed on day 14,
and spleen and inguinal lymph nodes were harvested. Spleno-
cytes were enriched for T lymphocytes using a pan–T cell
isolation kit (Miltenyi Biotech, Sunnyvale, CA). T cell purity
was 75–95%. Single-cell suspensions of lymph nodes were
prepared and used in culture. CD4 T cells were purified
using EasySep kits from StemCell Technologies (Vancouver,
British Columbia, Canada).
In vitro culture of T lymphocytes and DCs. T lympho-
cytes were cultured with DCs or IL-4 DCs at a ratio of 40:1
with anti-CD3 (clone 1452C11; BD PharMingen) or 100 g/ml
of T cell culture–grade collagen (Chondrex) for 72 hours
(anti-CD3) or 120 hours (collagen) in lymphocyte medium, as
previously described (24). Culture supernatants were frozen,
and cytokine levels were measured by ELISA. Neutralizing
anti–IL-4 antibody (clone 11B11; BD PharMingen) was used at
1 g/ml, anti-p19 antibody (clone G23-8; eBioscience, San
Diego, CA) at 5 and 10 g/ml, anti–IL-12 p70 antibody (clone
18.2; eBioscience) at 1 or 5 g/ml, and anti-IFN antibody
(clone XMG1.2; BioLegend, San Diego, CA) at 1 or 10 g/ml.
When IL-4 (R&D systems) was added to DCs, 10 ng/ml was
used. IL-23 (eBioscience) was used at 10 and 100 ng/ml. IL-12
(eBioscience) was used at 1 ng/ml. Proliferation was assessed
by the incorporation of 3H-thymidine.
Induction of arthritis in mice. Male DBA mice ages
7–9 weeks were housed under specific pathogen–free condi-
tions. Chicken type II collagen was dissolved in 0.05M acetic
acid at a concentration of 2 mg/ml by stirring overnight at 4°C
and was then emulsified in an equal volume of CFA. Collagen
(100 g) was injected intradermally at the base of the tail.
Arthritis was scored from day 21 using a scale of 0–4 per limb,
where 0  no swelling or redness, 1  swelling or redness in 1
digit, 2  mild swelling and redness involving the entire paw,
3  moderate swelling and redness involving the entire
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paw, and 4  severe swelling and redness involving the entire
paw. Mice were considered arthritic if they had a score of 3 in
at least 1 paw.
Mice with arthritis were killed on day 56, and T
lymphocytes were isolated from spleens. T lymphocytes were
then cultured with DCs or IL-4 DCs and collagen or anti-CD3.
Culture supernatants were collected at 72 or 96 hours and
analyzed for cytokines by ELISA. All protocols involving mice
were approved by the Committee on Use and Care of Animals,
University of Michigan, Ann Arbor.
Statistical analysis. ELISAs were performed in tripli-
cate. Data are presented as the mean  SEM. Statistical
Figure 1. Cytokine production by interleukin-4 (IL-4) dendritic cells (DCs) and untrans-
duced DCs after stimulation with CD40L. Untransduced DCs and IL-4 DCs were generated
as described in Materials and Methods. DCs or IL-4 DCs (1  106/ml) were stimulated with
10 g/ml of soluble CD40L (sCD40L) for 24 hours, with or without IL-4 (40 ng/ml) or
neutralizing antibody to IL-4 (IL-4; 10 g/ml), and supernatants were analyzed for A,
tumor necrosis factor (TNF) and interferon- (IFN), B, IL-6, and C, IL-10 by enzyme-
linked immunosorbent assay. Enzyme-linked immunosorbent assays were performed in
triplicate. Values are the mean and SEM. Results are from 1 experiment and are
representative of 3 independent experiments.
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analyses were performed using Student’s t-test or one-way
ANOVA. P values less than 0.05 were considered statistically
significant.
RESULTS
Cytokine profile of IL-4 DCs after stimulation
with CD40 ligand. We evaluated the cytokine profile of
IL-4 transduced DCs as compared with that of untrans-
duced DCs. DCs and IL-4 DCs were generated as
described in Materials and Methods. DCs or IL-4 DCs
were stimulated for 24 hours with recombinant CD40L,
with or without recombinant IL-4 (for DCs) or neutral-
izing antibodies to IL-4 (for IL-4 DCs). IL-4, in cultures
of untransduced DCs, was used at 40 ng/ml, since IL-4
DCs produce as much as 40 ng/ml of IL-4 per 1  106
cells in 24 hours. Supernatants were analyzed for various
cytokines by ELISA.
As shown in Figure 1A, the IL-4 DCs made more
TNF and IFN than did the untransduced DCs after
stimulation with CD40. These increases in TNF and
IFN were independent of IL-4. DCs and IL-4 DCs
produced similar quantities of IL-6 and IL-10 at baseline
and after stimulation with CD40L, which was not altered
by IL-4 (Figures 1B and C). Thus, immunoregulatory
effects of IL-4 DCs occur despite their ability to produce
augmented amounts of some proinflammatory cyto-
kines.
IL-4 DC–induced decrease in IL-17 production
by antigen-specific T cells. Experiments were next per-
formed to evaluate the effects of IL-4 DCs on splenic T
cells and draining lymph node cells during the induction
phase of CIA. DBA mice were immunized with collagen
and CFA intradermally at the base of the tail. Two
weeks later, splenic T lymphocytes were isolated and
Figure 2. Role of interleukin-23 (IL-23) in IL-4 dendritic cell (DC)–mediated suppression of IL-17
production by T cells. T lymphocytes purified from the spleens of collagen-immunized mice were cultured
with DCs or IL-4 DCs in the presence of A and B, collagen (Coll) or C and D, anti-CD3 (CD3), and
culture supernatants were collected after 5 days (for collagen) or 3 days (for anti-CD3) and analyzed by
enzyme-linked immunosorbent assay for IL-17 and interferon- (IFN). Enzyme-linked immunosorbent
assays were performed in triplicate. Values are the mean and SEM. Results are from 1 experiment and are
representative of 4 independent experiments.   P  0.05 by Student’s t-test.
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cultured with DCs or IL-4 DCs and anti-CD3 or collagen
for 4–5 days. Culture supernatants were collected and
analyzed by ELISA for IL-17 and IFN.
The results showed that T cells rechallenged with
collagen in the presence of IL-4 DCs produced less
IL-17 than did T cells cultured with untransduced DCs
(Figure 2A). There was no change in IFN secretion
from T cells when cultured with either untransduced
DCs or IL-4 DCs (Figure 2B). Similar effects on IL-17
and IFN production were seen with lymphocytes from
draining lymph nodes cultured with IL-4 DCs (data not
shown). Such responses were not seen when an unre-
lated antigen, keyhole limpet hemocyanin, was used for
rechallenge in collagen-immunized mice (data not
shown). T cells or CD4 T cells cultured with DCs or IL-4
DCs at different ratios (20:1 or 40:1) yielded similar
results (data not shown). Splenic T cells or CD4 T cells
cultured with IL-4 DCs as compared with DCs showed a
slightly reduced proliferative response, but this differ-
ence was not statistically significant (data not shown).
These data show that T cells produce IL-17 as an early
response to collagen and that the production of IL-17
can be regulated by IL-4 DCs, even when IFN produc-
tion by sensitized Th1 cells is refractory to regulation by
IL-4 DCs.
We also analyzed the cytokine response of splenic
T cells to a polyclonal stimulus, anti-CD3, in the pres-
ence of untransduced DCs or IL-4 DCs. T cells cultured
with IL-4 DCs and anti-CD3 produced less IL-17 and
less IFN than did T cells cultured with DCs (Figures 2C
and D). Similar reductions in IL-17 and IFN produc-
tion were observed with unfractionated splenocytes and
with lymphocytes from draining lymph nodes (data not
shown).
Effect of neutralizing IL-4 on the immunoregu-
latory effects of IL-4 DCs. T cells cultured in the
presence of IL-4 DCs produced less IL-17, but IL-4 DCs
have other alterations in gene expression beyond pro-
duction of IL-4. We therefore studied the contribution
of IL-4 to the immunoregulatory effects of IL-4 DCs by
neutralizing IL-4 or by the addition of IL-4 to the
cocultures with T cells. Splenic T cells from collagen-
immunized mice were stimulated with collagen in the
presence of untransduced DCs and recombinant IL-4 or
in the presence of IL-4 DCs and neutralizing anti–IL-4
antibody. Culture supernatants were analyzed for IL-17.
Addition of IL-4 to cultures with untransduced DCs
reduced the level of IL-17 production by T cells. Neu-
tralizing IL-4 in cultures containing IL-4 DCs resulted in
increased production of IL-17 (Figure 3). This finding
confirms that the IL-17 response in T cells is mediated
by IL-4 that is secreted from IL-4 DCs.
Role of IL-23 in IL-17 production by T cells in the
presence of IL-4 DCs. While IL-23 is not necessary for
the generation of IL-17 cells, it augments IL-17 produc-
tion from memory Th17 cells (18). IL-23 is composed of
2 subunits, p19 and p40. Mice with the p19 knockout
develop less severe arthritis (19). We next analyzed the
role of IL-23 in IL-17 production in this system. We
evaluated this by adding IL-23 or neutralizing antibody
to the p19 subunit of IL-23 in cultures of T cells with
IL-4 DCs and collagen. Our data showed that the
addition of 100 ng/ml of IL-23 only modestly restored
IL-17 production by T cells in the presence of IL-4 DCs
(Figure 4A). The addition of 10 ng/ml of IL-23 had no
effect on IL-17 levels (data not shown). Although IL-23
at 100 ng/ml resulted in some increase in the IL-17
response, the levels were still lower than those produced
by T cells in the presence of untransduced DCs.
Neutralizing IL-4 in cultures containing IL-4 DCs
resulted in a much greater increase in IL-17 as compared
with reconstituting the IL-23 level in the presence of
IL-4 DCs. The increased IL-17 production after neutral-
ization of IL-4 was only partly reversed after neutralizing
the IL-23 with antibody to the p19 subunit. As expected,
Figure 3. Effect of neutralizing or adding interleukin-4 (IL-4) on
IL-17 production by T cells. Splenic T cells purified from collagen-
immunized mice were cultured either alone (–), with dendritic cells
(DCs), or with IL-4 DCs, with or without collagen. Anti–IL-4 antibody
(IL-4; 1 g/ml) or IL-4 (10 ng/ml) was added at the beginning of
culture. Supernatants were collected after 4 days of culture and
analyzed for IL-17 by enzyme-linked immunosorbent assay. Enzyme-
linked immunosorbent assays were performed in triplicate. Values are
the mean and SEM. Results are from 1 experiment and are represen-
tative of 5 independent experiments.   P  0.05 by Student’s t-test.
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neutralizing antibody to the IL-23 p19 subunit did not
alter IL-17 production by T cells in the presence of IL-4
DCs. Similar changes in IL-17 regulation were seen with
IL-17 enzyme-linked immunospot (ELISpot) assays
(data not shown).
These findings suggest that the suppression of
IL-17 production by T cells in the presence of IL-4 DCs
is not due to insufficient IL-23 and that IL-4 has a direct
and dominant effect over IL-23 on the production of
IL-17 by T cells. Indeed, IL-17 production by T cells in
Figure 4. Suppressive effect of interleukin-4 (IL-4) dendritic cells (DCs) on IL-17 production by T cells is only partially
mediated by underproduction of IL-23. A, Splenic T cells from collagen-immunized mice were cultured with collagen
and either IL-4 DCs or untransduced DCs and then with neutralizing antibodies to IL-4 (IL-4; 1 g/ml), IL-23 p19
subunit (p19; 10 g/ml), or IL-23 (100 ng/ml). Supernatants were collected after 5 days of culture and analyzed for
IL-17 by enzyme-linked immunosorbent assay (ELISA). B, Splenic T cells from collagen-immunized mice were cultured
with DCs and collagen in the presence of IL-4 (1 or 10 ng/ml) and/or IL-23 (10 or 100 ng/ml). When both IL-23 and IL-4
were added, IL-4 was used at 10 ng/ml. Culture supernatants were collected after 5 days and analyzed for IL-17 by
ELISA. C, Splenic T cells from collagen-immunized mice were cultured with untransduced DCs and collagen (Coll).
Antibody to the p19 subunit of IL-23 (10 g/ml) was added at the initiation of culture. Supernatants were collected after
5 days of culture and analyzed for IL-17 by ELISA. Enzyme-linked immunosorbent assays were performed in triplicate.
Values are the mean and SEM. Results are from 1 experiment and are representative of 3 independent experiments.
  P  0.05 by Student’s t-test.
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the presence of IL-4 DCs and neutralizing antibody to
IL-4 was greater than that observed when T cells were
cultured with untransduced DCs. We also found that the
augmented IL-17 response seen after treatment with
neutralizing IL-4 was only partly suppressed by blocking
IL-23. It is possible that costimulatory molecule interac-
tions, such as CD28/CD80–CD86 and inducible costimu-
lator (ICOS)/ICOSL, may be supporting IL-17 produc-
tion in this setting.
We confirmed our data shown in Figure 4A by
using untransduced DCs instead of IL-4 DCs. As shown
in Figure 4B, suppression of IL-17 was evident when T
cells were cultured with untransduced DCs and IL-4.
IL-23 has been viewed as a primary driver of the IL-17
Figure 5. Suppression of interleukin-17 (IL-17) by IL-4 dendritic cells (DCs) in an IL-12– and interferon- (IFN)–independent manner.
Splenic T cells were prepared from collagen-immunized mice and cultured with untransduced dendritic cells (DCs) or IL-4 DCs and collagen.
A, IL-4 (10 ng/ml), and/or IL-12 (1 ng/ml) was added at the initiation of culture. Supernatants were collected after 5 days of culture and
analyzed for IL-17 by enzyme-linked immunosorbent assay (ELISA). B, Neutralizing antibody to IL-12 p70 (p70; 1 g/ml or 5 g/ml) was
added to cultures of T cells with collagen and IL-4 DCs. Supernatants were collected after 5 days of culture and analyzed for IL-17 and IFN
by ELISA. C, Neutralizing antibody to IFN (IFN-; 1 g/ml or 10 g/ml) was added to cultures of T cells with collagen and DCs or IL-4
DCs. Supernatants were collected after 5 days of culture and analyzed for IL-17 by ELISA. Enzyme-linked immunosorbent assays were
performed in triplicate. Values are the mean and SEM. Results are from 1 experiment and are representative of 3 independent experiments.
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response (6,18), and we found that adding IL-23 in-
creased the production of IL-17, but when IL-4 and
IL-23 were added together, there was no increase in
IL-17 production. This effect was seen even at a very
high concentration of IL-23 (100 ng/ml). Thus, IL-4
renders the T cells resistant to the IL-23–mediated
production of IL-17.
To further study the role of IL-23 in this system,
we set up cultures of T cells with untransduced DCs and
used antibodies to the p19 subunit of IL-23. We found
only a slight decrease in IL-17 production after neutral-
ization of IL-23 (Figure 4C). It is possible that cell
surface costimulatory ligands and/or proinflammatory
cytokines other than IL-23 that are produced by DCs
contribute to IL-17 production by T cells in a collagen
rechallenge response.
Role of IL-12 and IFN in IL-4 DC–mediated
suppression of IL-17 production by T cells. IL-23 and
IL-12 share a common p40 subunit as well as a common
receptor subunit (30). IL-12 is a potent inducer of IFN
(19,30), and it has recently been shown that inhibition of
IFN can enhance the development of IL-17–producing
T cells (28). IL-4 DCs produce increased quantities of
IL-12 and IFN, as compared with untransduced DCs,
after stimulation with CD40L and lipopolysaccharide
(25) (Figure 1A). We therefore evaluated the role of
IL-12 and IFN in our system.
Splenic T cells from mice immunized with colla-
gen were cultured with collagen and DCs for 5 days
(Figure 5A). IL-12 (1 ng/ml) and/or IL-4 (10 ng/ml) or
anti–IL-4 (10 g/ml) was added at the initiation of
culture. Culture supernatants were analyzed for IL-17
and IFN by ELISA. The presence of IL-12 suppressed
IL-17 production (Figure 5A) and increased IFN pro-
duction (data not shown). The effects of IL-12 and IL-4
on IL-17 were comparable. There was a modest increase
in IL-17 production after neutralization of IL-4 in
cultures with untransduced DCs (data not shown), which
suggests that there were small amounts of endogenous
IL-4 in these cultures. We then neutralized IL-12 in
cultures of IL-4 DCs and T cells with neutralizing
antibodies to IL-12 p70 (Figure 5B). Neutralizing IL-12
had no effect on IL-17 production in the presence of
IL-4 DCs. As expected, neutralization of IL-12 resulted
in decreased IFN production in these cultures. This
suggests that although IL-12 can suppress IL-17, and
IL-4 DCs produce increased quantities of IL-12, sup-
pression of IL-17 production by IL-4 DCs is due to IL-4
and not IL-12.
IL-4 DCs produce increased quantities of IFN,
and IFN suppresses IL-17. To study the role of IFN in
IL-4 DC–mediated suppression of IL-17, T cells were
cultured with DCs or IL-4 DCs and neutralizing anti-
body to IFN (Figure 5C). As expected, neutralizing
IFN in cultures of T cells and DCs increased IL-17
production. Neutralizing IFN in cultures of T cells and
IL-4 DCs led to only a modest increase in IL-17, less
than that in cultures of T cells and DCs. This suggests
Figure 6. Lack of effect of interleukin-4 (IL-4) dendritic cells (DCs) on IL-17 production by T
lymphocytes from mice with end-stage arthritis. Arthritis was induced in mice by intradermal injection of
collagen and Freund’s complete adjuvant. Mice with arthritis (scores of at least 3 or 4 in 1 paw) were killed
on day 56 after collagen injection. T lymphocytes were prepared from spleens and cultured in vitro with
DCs or IL-4 DCs and either A, collagen or B, anti-CD3. Supernatants were collected after 3 days
(anti-CD3) or 4 days (collagen stimulation) of culture and analyzed for IL-17 by enzyme-linked
immunosorbent assay. Enzyme-linked immunosorbent assays were performed in triplicate. Values are the
mean and SEM. Results are from 1 experiment and are representative of 3 independent experiments.
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that while IFN produced by IL-4 DCs could account for
some of the suppression, IL-4 plays a major and domi-
nant role in suppression of IL-17 responses.
Effect of IL-4 DCs on IL-17 production by T cells
from mice with established arthritis. We have shown
that IL-4 DCs can modulate IL-17 production by
collagen-specific T cells during the early stages of CIA.
We also wanted to determine whether IL-4 DCs could
alter IL-17 production by T cells from mice with estab-
lished arthritis. Mice were immunized with collagen and
CFA and were monitored for arthritis as described in
Materials and Methods. Mice began to show signs of
arthritis on day 28, and 70% of the mice had scores of 3
in at least 1 paw. On day 56 after collagen immunization,
splenic T lymphocytes from mice with an arthritis score
of 3 in at least 1 paw were obtained and purified. Mice
that did not have arthritis and those that had maximum
scores of 1–2 were excluded. T cells were then cultured
with DCs or IL-4 DCs in the presence of collagen
(Figure 6A) or the polyclonal stimulus anti-CD3 (Figure
6B), and supernatants were collected for measurement
of IL-17 by ELISA. T cells from mice with late-stage
CIA produced similar quantities of IL-17 in the presence
and absence of IL-4 DCs, in either a polyclonal or a
collagen-specific response. It is possible that the pheno-
type of T cells that secrete IL-17 is stabilized by the time
the mice develop end-stage arthritis and is thus not
susceptible to reduction by IL-4 DCs.
DISCUSSION
The Th1/Th2 paradigm has recently been modi-
fied to include a third type of differentiated T helper
cell, called Th17, which secretes IL-17. Th17 cells have a
distinct lineage and do not share a developmental path-
way with Th1 or Th2 cells (28,29). IL-17 receptor is
ubiquitously expressed (1). IL-17 stimulates the produc-
tion of IL-1, TNF, IL-6, IL-8, G-CSF, and PGE2 from
macrophages and synoviocytes (2,5,31).
IL-23 augments IL-17 production by memory
Th17 cells, but is itself not sufficient to generate Th17
cells. Data from transgenic mice expressing a T cell
receptor for ovalbumin have shown that neutralization
of IFN and IL-4, in addition to the presence of IL-23,
enhances the generation of Th17 cells from naive CD4 T
cells in vitro. Once the Th17 phenotype is stabilized,
neutralization of IFN or IL-4 does not alter the IL-17
response (28). Th17 cells develop independently of
STAT-1, STAT-4, and STAT-6 signaling and the tran-
scription factors T-bet and c-Maf (28,29). Experiments
done with CD28- or ICOS-knockout mice have shown
that these costimulatory molecules also play a role in the
generation of Th17 cells (29). Recent studies have
shown that IL-6, in combination with transforming
growth factor  (TGF), inhibits the generation of
FoxP3-expressing T regulatory cells and induces the
generation of Th17 cells (32–34). TGF is not only
critical to the development of Th17 cells, but it also
induces the expression of IL-23 receptor, which facili-
tates Th17 survival and expansion (34). These studies
provide evidence that Th1, Th2, and Th17 cells develop
from naive T cells and that the generation of T regula-
tory cells and Th17 cells occurs via alternative pathways,
which are selected according to the presence or absence
of IL-6.
IL-17 has been detected and has been proposed
to be pathogenic in systemic sclerosis (35), systemic
lupus erythematosus (36), and RA (10). Anti–IL-17
antibody was shown to reduce the incidence and severity
of experimental autoimmune encephalomyelitis, even
though the splenic and lymph node cells obtained from
the mice retained the capacity to produce IL-17. There
was a lack of recruitment of Th17 cells into the brain
secondary to a reduced expression of CCL2, CCL17, and
CXCL1, suggesting that IL-17 can increase the expres-
sion of several lymphotactic chemokines. Transgenic
mice that overexpressed IL-17 in the lung epithelium
also had increased levels of several chemokines (29).
Neutralization of IL-17 has been shown to sup-
press the onset, and decrease the severity, of arthritis in
animal models of RA (13,14,37). IL-17–/– mice have
reduced collagen-specific T cell responses during the
initiation phase of arthritis and a reduced incidence and
intensity of arthritis (15). Overexpression of IL-4 has
been shown to down-regulate IL-17 and prevent carti-
lage destruction and bone erosion (38,39).
Investigators in our laboratory have previously
shown that when bone marrow–derived DCs that over-
express IL-4 are injected into mice during the initiation
phase of CIA, the incidence and severity of arthritis are
reduced and that IL-4 DCs differentially regulate the
production of IL-12/IL-23 after stimulation through
their CD40 receptors. Since IL-17–knockout mice have
a reduced incidence of arthritis and since local overex-
pression of IL-4 down-regulates IL-17 expression in the
joints, we hypothesized that IL-4 DCs may be reducing
the incidence of arthritis by decreasing the production of
IL-17 by collagen-specific T cells. To study this, we
isolated splenic T lymphocytes from DBA mice 15 days
after collagen immunization and cultured them in the
presence of untransduced or IL-4–transduced DCs in a
collagen rechallenge response. IL-17 was measured in
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the culture supernatants by ELISA or ELISpot. Our
data showed that T cells cultured in the presence of IL-4
DCs produced less IL-17 and similar quantities of IFN
in a collagen-specific response. This suggests that IL-17
is a cytokine of paramount importance in the early
response to collagen and that IL-4 DCs reduce the
incidence and severity of arthritis by decreasing the
IL-17 response in T cells, even when the IFN response
is fixed. It is likely that this muted IL-17 response during
the early stages of arthritis translates into a reduced
incidence and severity of arthritis. A decrease in both
IL-17 and IFN was only seen when the polyclonal
stimulus anti-CD3 was used. These effects were not
limited to splenic T cells, but were also seen in lympho-
cytes from draining lymph nodes.
IL-4 DCs produce excessive IL-4, and we evalu-
ated the effect of neutralizing IL-4 in cultures of IL-4
DCs or adding IL-4 to cultures with untransduced DCs.
Our results showed that IL-4 can decrease the produc-
tion of IL-17 by T cells cultured with DCs and collagen.
Recent studies by Harrington et al (28) and Park et al
(29), which were published when the experiments pre-
sented herein were near completion, have also shown
that IL-4 can influence the production of IL-17, in that
neutralizing IL-4 can lead to increased levels of IL-17. In
our studies, neutralizing IL-4 in T cells cultured with
IL-4 DCs resulted in reconstitution of the abrogated
IL-17 response to collagen.
IL-23 has been implicated as a primary driver of
IL-17 production by memory Th17 cells (17,18). We
hypothesized that IL-4 may be reducing the production
of IL-17 through an IL-23–dependent mechanism, pos-
sibly by down-regulating the production of IL-23 by
DCs. If this were the case, then adding recombinant
IL-23 would increase the production of IL-17. However,
we found that IL-23 at 10 ng/ml did not alter IL-17 levels
and that IL-23 at 100 ng/ml only modestly increased
IL-17 production in the presence of IL-4 DCs. This
amount of IL-23 is several hundred times higher than
the amount of IL-4 present in the cultures. When the
same amount of IL-23 was added to T cells cultured with
untransduced DCs and collagen, we observed a much
higher production of IL-17. This suggests that the IL-4–
mediated suppression of IL-17 is not due to suppression
of IL-23 production by IL-4 DCs. The data also indicate
that IL-4 renders the T cells resistant to IL-23, at least
with respect to IL-17 production, and that this resistance
is not overcome by excess concentrations of IL-23.
Primed T cells cultured with untransduced DCs and
collagen showed high levels of IL-17 production, which
was suppressed by IL-4 and was not reversed by the
addition of IL-23. These results provide further proof of
IL-23 resistance in the presence of IL-4 and suggest that
down-regulation of IL-17 by IL-4–transduced DCs is
mediated by IL-4 and not by the retroviral transduction
of DCs.
Furthermore, the increase in IL-17 production
after neutralization of IL-4 was only modestly sup-
pressed by the addition of anti-p19 antibody, thus sug-
gesting that T cell production of IL-17 is only partly
mediated by IL-23 in T cells cultured with IL-4 DCs or
with untransduced DCs. It is likely that cognate costimu-
latory molecules play a role in the production of IL-17
by primed T cells obtained during the early stage of CIA.
IL-12, which shares a common subunit with IL-
23, drives IFN production in T cells (40). Neutralizing
IFN has been shown to increase the generation of Th17
cells (28,29). IL-4 DCs produce increased amounts of
IL-12 and IFN after stimulation with lipopolysaccha-
ride or CD40L (25). We also evaluated the effect of
IL-12 and IFN in our system. We found that IL-12
suppressed IL-17 production, but the effect of IL-4 DCs
on IL-17 production was independent of IL-12, since the
IL-17 response was not restored by blocking IL-12.
Neutralizing IFN did not reconstitute the IL-17 re-
sponse, which provides further evidence that the IL-4
DC–mediated suppression of IL-17 is robust and domi-
nant over IFN and is not secondary to excess IFN
that is produced by IL-4 DCs or by T cells influenced
by IL-12.
The mechanism underlying the IL-4–mediated
suppression of IL-17 is not known. However, it is robust
and dominant over IL-23 and IFN. It is possible that
IL-4 down-regulates the expression of IL-23 receptor or
induces T regulatory cells, which then suppress IL-17
production. It is also possible that IL-4 blocks the
costimulatory molecule–mediated production of IL-17
by down-regulating receptor/ligand expression or func-
tion. IL-4 binding to its receptor on T cells could block
intracellular signaling events that would otherwise have
led to the production of IL-17.
T cells from mice with end-stage arthritis failed to
decrease their production of IL-17 when cultured in the
presence of IL-4 DCs. This suggests that while IL-4 DCs
modulate the early initiation phase of arthritis by de-
creasing IL-17 production by T cells, they are unable to
elicit such a response during the late phase of arthritis. It
has been shown that IL-4 DCs can suppress CIA early
after its clinical onset (41). Our data seem not to be in
complete agreement with those obtained in previous
studies by Lubberts et al (39), who reported that local
injection of a viral vector expressing IL-4 resulted in the
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amelioration of established inflammation and the reduc-
tion of IL-17 in the injected joint. It is possible, however,
that the systemic IL-17 response in mice with established
arthritis is regulated differently by IL-4 than is the local
expression of IL-17 in arthritic joints.
The cytokine imbalance in CIA is difficult to
explain by the prevailing Th1/Th2 paradigm and, in-
stead, is likely to involve other cytokines, especially
IL-17. The data currently available suggest that the
IL-17–producing cells remain sensitive to IL-4 DCs for a
limited interval following the appearance of joint inflam-
mation. It is possible that, while the IL-17 response
during the early initiation phase of CIA is amenable to
regulation by IL-4, the IL-17 response during end-stage
arthritis is mediated by a distinct set of costimulatory
signals that cannot be overcome by IL-4. Alternatively,
the IL-17–producing T cells in end-stage arthritis are at
a point in their differentiation at which IL-4 receptor
signaling is defective.
Distinct windows appear to exist in the IL-17
response from T cells in arthritis, during which it can be
modulated by changing the cytokine environment. Once
the IL-17 response is stabilized, as in end-stage arthritis,
then such changes are not possible or, at least, are more
difficult to accomplish. This paradigm helps to explain
the early events in immune-mediated arthritis and pos-
sible ways to modulate key pathogenic responses. Such
an understanding will help in the development of novel
therapies targeted to IL-17 in RA. Further studies
evaluating the role of costimulatory molecules in the
generation and regulation of IL-17–producing T cells, as
well as the in vivo IL-17 response in CIA and its
modulation by administration of IL-4 DCs, are ongoing.
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